אסטוניה - אסטונית - Ravimiamet

aristo pharma gmbh - tikagreloor - õhukese polümeerikattega tablett - 90mg 14tk; 90mg 56tk; 90mg 100tk; 90mg 60tk; 90mg 168tk

אסטוניה - אסטונית - Ravimiamet

gedeon richter plc. - tikagreloor - õhukese polümeerikattega tablett - 60mg 56tk; 60mg 168tk

אסטוניה - אסטונית - Ravimiamet

gedeon richter plc. - tikagreloor - õhukese polümeerikattega tablett - 90mg 60tk; 90mg 168tk; 90mg 56tk; 90mg 120tk

אסטוניה - אסטונית - Ravimiamet

sia elvim - tikagreloor - õhukese polümeerikattega tablett - 90mg 56tk

אסטוניה - אסטונית - Ravimiamet

farmak international sp. z o.o. - tikagreloor - õhukese polümeerikattega tablett - 90mg 100tk; 90mg 56tk; 90mg 60tk

אסטוניה - אסטונית - Ravimiamet

farmaprojects s.a.u. - tikagreloor - õhukese polümeerikattega tablett - 60mg 168tk; 60mg 56tk

אסטוניה - אסטונית - Ravimiamet

farmaprojects s.a.u. - tikagreloor - õhukese polümeerikattega tablett - 90mg 98tk; 90mg 60tk; 90mg 56tk; 90mg 168tk; 90mg 100tk

אסטוניה - אסטונית - Ravimiamet

tad pharma gmbh - tikagreloor - õhukese polümeerikattega tablett - 60mg 180tk; 60mg 14tk; 60mg 168tk; 60mg 60tk

אסטוניה - אסטונית - Ravimiamet

tad pharma gmbh - tikagreloor - õhukese polümeerikattega tablett - 90mg 180tk; 90mg 100tk; 90mg 60tk; 90mg 168tk

האיחוד האירופי - אסטונית - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivakaftoor - tsüstiline fibroos - muud hingamisteede tooted - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 ja 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.